or a tautomeric form thereof and/or pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein:

A^1 represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, the [substituents for the heterocyclyl group being up to 4] substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of: C_{1-12}-[alkl] alkyl, C_{1-12}-alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted;

R^1 represents a hydrogen atom, a C_{1-12}-alkyl group, [a C_{1-12}-alkyl group,] a C_{1-6} alkylcarbonyl group, an aryl-C_{1-12}-alkyl group the aryl moiety being substituted or unsubstituted, or a substituted or unsubstituted aryl group;

any aryl group being phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C_{1-12}-alkyl, phenyl, C_{1-12}-alkoxy, halo-C_{1-12}-alkyl, hydroxy, amino, nitro, carboxy, C_{1-12}-alkoxycarbonyl, C_{1-12}-alkoxycarbonyl-C_{1-12}-alkyl, C_{1-12}-alkylcarbonyloxy, or a C_{1-12}-alkylcarbonyl group;

R^2 and R^3 each represent hydrogen, or R^2 and R^3 together represent a bond;

A^2 represents a benzene ring having three optional substituents which may be selected from halogen, substituted or unsubstituted alkyl or alkoxy; substituents for the alkyl group being selected from the groups consisting of halogen, C_{1-12}-alkyl, phenyl, [C_{1-12}-alkyl, phenyl,] C_{1-12}-alkoxy, halo-C_{1-12}-alkyl, hydroxy, amino, nitro, carboxy, C_{1-12}-alkoxycarbonyl, C_{1-12}-alkoxycarbonyl-C_{1-12}-alkyl, C_{1-12}-alkylcarbonyloxy, or C_{1-12}-alkylcarbonyl; and

n represents an integer in the range of from 2 to 6.

~~55~~ ~~56.~~ (Amended) A method for the treatment and/or prophylaxis of diseases selected from the group consisting of hyperglycaemia[,] and hyperlipidaemia[, hypertension, cardiovascular diseases and eating disorders] in a human or a non-human mammal which comprises administering to said human or non-human mammal in need thereof, an effective, non-toxic, amount of a compound of formula (I) according to claim ~~52,~~ or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof.

Please add new claim 57 as follows:

--57. A method for the treatment and/or prophylaxis of diseases selected from the group consisting of hypertension, cardiovascular diseases and eating disorders in a human or a non-human mammal which comprises administering to said human or non-human mammal in need thereof, an effective, non-toxic,